Compare Honest Company Inc (HNST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Recursion Pharmaceuticals Inc — how do they compare? Honest Company Inc trades at $5.05 (market cap $533.20M), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HNST | RXRX | |
|---|---|---|
Market Cap | $533.20M | $2.14B |
Volume | 1,990,155 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $6.79 |
52-Week Low | $2.10 | $2.84 |
Typical Hold Time | 39 Days | 23 Days |
Enterprise Value | $436.81M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $4.99, up 1.22% today, with a bearish technical signal despite recent positive earnings momentum. The company shows mixed fundamentals with revenue of $371.32M in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations with $0.04 EPS, and institutional interest is growing with BlackRock's $25.66M investment in August 2026.
The stock faces headwinds from persistent unprofitability and declining revenue projections for 2026, though strategic exits are improving margins. Analyst consensus is mixed with a $5.30 price target, suggesting limited upside. Key risks include execution on profitability and competitive pressures in personal care markets.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
